Nike Stock Slides as Revenue Miss Clouds Turnaround 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
WordPress Malware Uses Ethereum to Evade Removal 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Malaysia Aviation Group to Buy Airbus SAE Unit 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
